Scanning the diagnostic horizon – 100,000 and counting

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Prenuvo CEO on the role of whole body MRI tech and how AI is reducing costs and improving efficiency in diagnostics.

Market leader Prenuvo has set a new standard in preventative healthcare, completing over 100,000 whole-body MRI scans – a major milestone for both the company and the broader imaging field. Its advanced technology enables full-body MRI scans in under an hour, capturing over one billion data points and generating significantly more clinical-grade images than conventional MRI systems. In 2024, Prenuvo raised $120 million in Series B funding to further its mission of transforming early disease detection. The company also secured FDA clearance for its Prenuvo Body Composition report, an AI-driven tool that provides a detailed analysis of visceral fat, liver fat, muscle volume and key organ measurements – insights that could be crucial for metabolic and cardiovascular health.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE